Efficacy and Safety of Pirfenidone Treatment in HPS-ILD
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This research study will explore the safety and efficacy of the drug, pirfenidone, in
patients with a diagnosis of Hermansky-Pudlak Syndrome (HPS) who have an associated
interstitial lung disease (ILD) over a planned period of 56 weeks.